[Top][All Lists]
[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Re: [Gnumed-devel] where are we at?
From: |
Elizabeth Dodd |
Subject: |
Re: [Gnumed-devel] where are we at? |
Date: |
Sun, 15 Dec 2002 10:03:42 +1100 |
User-agent: |
KMail/1.4.3 |
-----BEGIN PGP SIGNED MESSAGE-----
Hash: SHA1
> (IMHO, if an "adjuvant" has serious implications for indications,
> adverse effects, etc., then its not really an adjuvant for our purposes:
> it should have its own entry in "constituents")
>
The two most common adjuvants are wheat based or lactose. Both of these have
serious implications for some people, and the drug information is often
lacking adjuvants.
Where the information exists for these it certainly should be listed as a
consitiuent, for when searching for gluten-free products this would allow an
easier search.
I have also persons allergic to colours but these are usually easier to spot
and check what sort of blue or yellow has been used.
Incidentally there is a rice-based adjuvant available but it is little used
despite the many advantages to those with coeliac disease. As this seems to
be a Celtic gene it won't be such a trouble for groups who weren't affected
by the Irish diaspora.
Liz
-----BEGIN PGP SIGNATURE-----
Version: GnuPG v1.0.6 (GNU/Linux)
Comment: For info see http://www.gnupg.org
iEYEARECAAYFAj37uM4ACgkQSpMfinVOW106hACdHAkYcoKjOoSbe31yQM8zAwly
q/4AoJOjoao1ox8thYoqiivE+kCO9ncT
=PxjK
-----END PGP SIGNATURE-----
- [Gnumed-devel] where are we at?, Ian Haywood, 2002/12/14
- Re: [Gnumed-devel] where are we at?, Horst Herb, 2002/12/14
- Re: [Gnumed-devel] where are we at?, Hilmar Berger, 2002/12/14
- Re: [Gnumed-devel] where are we at?, Ian Haywood, 2002/12/14
- Re: [Gnumed-devel] where are we at?, Karsten Hilbert, 2002/12/21
- [Gnumed-devel] script tables, Karsten Hilbert, 2002/12/22
- Re: [Gnumed-devel] script tables, Hilmar Berger, 2002/12/23
- Re: [Gnumed-devel] script tables, Karsten Hilbert, 2002/12/23
Re: [Gnumed-devel] where are we at?, Elizabeth Dodd, 2002/12/14
Re: [Gnumed-devel] where are we at?, Karsten Hilbert, 2002/12/22